Levosimendan - a calcium sensitising agent with potential anti-arrhythmic properties

International Journal of Clinical Practice
M KowalczykJ Rysz

Abstract

Levosimendan is a 'Ca(2+)sensitiser', which exerts its inotropic effect by increasing the affinity of troponin C for Ca(2+), directly stabilising the Ca(2+)-induced conformation of troponin C. It leads to a positive inotropic effect without impairing diastolic relaxation and causing cytosolic Ca(2+) ion overload, which might result in cardiac myocyte dysfunction, arrhythmias and cell death. Levosimendan may also have significant anti-inflammatory properties. Data from various studies suggest that levosimendan might have anti-arrhythmic effects, although the outcome of clinical trials on the effect of this agent in (for example) atrial fibrillation (AF) remains controversial. Currently, on the basis of available data, it is especially worth emphasising the potential role of this drug in the termination of AF after cardiac surgery, which significantly influences early- and long-term morbidity and mortality. This review considers the putative anti-arrhythmic properties of levosimendan and discusses the potential clinical application of such a drug.

References

May 1, 1995·Journal of Cardiovascular Pharmacology·H HaikalaI B Lindén
Nov 25, 2000·Journal of the American College of Cardiology·M S NieminenW J Remme
May 23, 2001·Drugs·D P FiggittK L Goa
Nov 2, 2001·European Journal of Pharmacology·D M KopustinskieneN E Saris
Jul 23, 2002·Lancet·F FollathUNKNOWN Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study
Oct 25, 2002·International Journal of Clinical Pharmacology and Therapeutics·M KivikkoP J Pentikäinen
Jan 29, 2005·Anaesthesia and Intensive Care·W Plöchl, A Rajek
Aug 24, 2005·Journal of Cardiovascular Pharmacology·E GrossiniG Vacca
Sep 27, 2005·The American Journal of Cardiology·Alexandre MebazaaStéphane Welschbillig
Sep 27, 2005·The American Journal of Cardiology·Ferenc FollathJosé Silva Cardoso
Mar 2, 2006·Anesthesiology·Wolfgang G Toller, Christian Stranz
Mar 7, 2006·Progress in Cardiovascular Diseases·E Kevin Heist, Jeremy N Ruskin
Mar 28, 2006·The Annals of Thoracic Surgery·Shahzad G Raja, Benson S Rayen
Mar 28, 2006·Circulation Journal : Official Journal of the Japanese Circulation Society·Maciej BanachJanusz Zaslonka
May 23, 2006·European Journal of Heart Failure·Athanasios TrikasChristodoulos Stefanadis
Jun 13, 2006·International Journal of Cardiology·Panagiotis KorantzopoulosJohn A Goudevenos
Aug 8, 2006·Journal of Cardiovascular Pharmacology and Therapeutics·Julius Gy PappAgnes S Végh
Oct 26, 2006·The Annals of Thoracic Surgery·Philippe-Primo CaimmiGiovanni Teodori
Mar 17, 2007·Pharmacology & Therapeutics·Charalambos AntoniadesChristodoulos Stefanadis
May 3, 2007·JAMA : the Journal of the American Medical Association·Alexandre MebazaaUNKNOWN SURVIVE Investigators
Jul 27, 2007·American Journal of Hematology·Kürşat KaptanErsoy Işik
Sep 26, 2007·European Journal of Anaesthesiology·D YapiciU Oral
Oct 30, 2007·Cellular & Molecular Biology Letters·Mariusz PiechotaJacek Rysz
Nov 21, 2007·The Journal of Thoracic and Cardiovascular Surgery·Maciej BanachJan Henryk Goch
Jan 16, 2008·Heart·Christopher J Boos, Gregory Y H Lip
Oct 17, 2008·Journal of Cardiothoracic and Vascular Anesthesia·Stefan G De HertPhilippe J Van der Linden
Oct 24, 2008·European Journal of Heart Failure·Markku S NieminenToni Sarapohja
Nov 26, 2008·Heart Failure Clinics·Peter S Pang, Mihai Gheorghiade
Dec 23, 2008·Journal of Cardiothoracic and Vascular Anesthesia·Tong LiuGang Xu
Jan 23, 2009·European Journal of Heart Failure·Alexandre MebazaaAlain Cohen-Solal
Feb 17, 2009·Journal of Cardiothoracic and Vascular Anesthesia·Alberto ZangrilloGiovanni Landoni
Jun 23, 2009·Current Vascular Pharmacology·Maciej BanachOttavio Alfieri

❮ Previous
Next ❯

Citations

Jul 13, 2011·Annals of Medicine·Dariusz KozlowskiMaciej Banach
Feb 21, 2018·Biomedit︠s︡inskai︠a︡ khimii︠a︡·V A KudinovA I Archakov

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Related Papers

Anadolu Kardiyoloji Dergisi : AKD = the Anatolian Journal of Cardiology
Osman Can YontarIzzet Tandogan
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Martín J García González, Alberto Domínguez Rodríguez
© 2021 Meta ULC. All rights reserved